If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
It is the first branded generic alternative to Fostair 100/6 pMDI
The country’s strength lies not just in technology availability but in adoption behaviour
Medanta expanded its bed capacity by 20% during the year
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
Subscribe To Our Newsletter & Stay Updated
